Emerging approaches to polypharmacy among older adults

被引:21
|
作者
Mehta, Raaj S. [1 ,2 ,3 ]
Kochar, Bharati D. [1 ,2 ,3 ]
Kennelty, Korey [4 ,5 ]
Ernst, Michael E. [4 ,5 ]
Chan, Andrew T. [1 ,2 ,3 ]
机构
[1] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Massachusetts Gen Hosp, Clin & Translat Epidemiol Unit, Boston, MA 02114 USA
[4] Univ Iowa, Coll Pharm, Dept Pharm Practice & Sci, Iowa City, IA USA
[5] Univ Iowa, Carver Coll Med, Dept Family Med, Iowa City, IA USA
来源
NATURE AGING | 2021年 / 1卷 / 04期
基金
美国国家卫生研究院;
关键词
ADVERSE DRUG EVENTS; THE-COUNTER MEDICATION; UNITED-STATES; STOPP/START CRITERIA; RISK-FACTORS; HEALTH; THERAPY; PRESCRIPTION; IMPROVEMENT; ASSOCIATION;
D O I
10.1038/s43587-021-00045-3
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Polypharmacy is a leading health concern entangled with many geriatric syndromes. This Review provides an overview of the current research landscape and a critical appraisal of existing and emerging approaches to address polypharmacy. Polypharmacy is a major health issue for older adults. Entangled with several geriatric syndromes, including frailty, falls and cognitive decline, research focused on polypharmacy has been challenged by heterogeneity in its definition, confounding by comorbidities and limited prospective data. In this Review, we discuss varying definitions for polypharmacy and highlight the need for a uniform definition for future studies. We critically appraise strategies for reducing medication prescriptions and implementing deprescribing as a mechanism to reduce the potential harmful effects of polypharmacy. As we look to the future, we assess the role of novel analytics and high-throughput technology, including multiomics profiling, to advance research in polypharmacy and the development of new strategies for risk stratification in the age of precision medicine.
引用
收藏
页码:347 / 356
页数:10
相关论文
共 50 条
  • [1] Emerging approaches to polypharmacy among older adults
    Raaj S. Mehta
    Bharati D. Kochar
    Korey Kennelty
    Michael E. Ernst
    Andrew T. Chan
    Nature Aging, 2021, 1 : 347 - 356
  • [2] Forms of trust and polypharmacy among older adults
    Ross, Alison
    Gillett, James
    AGEING & SOCIETY, 2021, 41 (11) : 2583 - 2598
  • [3] Prevalence of multimorbidity and polypharmacy among adults and older adults: a systematic review
    Nicholson, Kathryn
    Liu, Winnie
    Fitzpatrick, Daire
    Hardacre, Kate Anne
    Roberts, Sarah
    Salerno, Jennifer
    Stranges, Saverio
    Fortin, Martin
    Mangin, Dee
    LANCET HEALTHY LONGEVITY, 2024, 5 (04): : e287 - e296
  • [4] Polypharmacy in Older Adults
    Canio, Wynnelena C.
    CLINICS IN GERIATRIC MEDICINE, 2022, 38 (04) : 621 - 625
  • [5] Sources of medication omissions among hospitalized older adults with polypharmacy
    Shah, Avantika Saraf
    Hollingsworth, Emily Kay
    Shotwell, Matthew Stephen
    Mixon, Amanda S.
    Simmons, Sandra Faye
    Vasilevskis, Eduard Eric
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2022, 70 (04) : 1180 - 1189
  • [6] Sarcopenia and polypharmacy among older adults: A scoping review of the literature
    Pana, Anastasia
    Sourtzi, Panayota
    Kalokairinou, Athina
    Velonaki, Venetia Sofia
    ARCHIVES OF GERONTOLOGY AND GERIATRICS, 2022, 98
  • [7] The Effects of Polypharmacy in Older Adults
    Hilmer, S. N.
    Gnjidic, D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (01) : 86 - 88
  • [8] PREVALENCE OF POLYPHARMACY IN OLDER ADULTS
    Hofmann, G.
    Hach, I.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 72 : 6 - 6
  • [9] DEPRESCRIBING IN OLDER ADULTS WITH POLYPHARMACY
    Zermansky, Arnold
    BMJ-BRITISH MEDICAL JOURNAL, 2024, 386
  • [10] About polypharmacy in older adults
    Jacob, Javier
    Pena, Barbara
    Herrero-Puente, Pablo
    MEDICINA CLINICA, 2021, 156 (06): : 307 - 307